McClarren Financial Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

McClarren Financial Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-553	Closed	-$2K	–	488
2023 Q1	$2K	Hold	553	–	–	﹤0.01%	295
2022 Q4	$3K	Hold	553	–	–	﹤0.01%	294
2022 Q3	$3K	Buy	+553	New	+$3.45K	﹤0.01%	274

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

McClarren Financial Advisors's CTIC Position: Q2 2023 in Review

McClarren Financial Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 553 shares — an estimated $2K sold.

McClarren Financial Advisors first reported a position in CTIC in Q3 2022 and held it in 3 quarters. The position peaked at $3K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

McClarren Financial Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
McClarren Financial Advisors sold 553 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $2K.
McClarren Financial Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 3 quarters.
McClarren Financial Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $3K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on McClarren Financial Advisors's 13F filing for Q2 2023, filed 7 Aug 2023.